Inspect the exact evidence boundary on structurevidence.org, then challenge it without entering a sales funnel. Submissions go directly to the single canonical challenge backend on structevidence.com for human review.
Public/commercial boundary: Challenge submission is free and separate from commercial verification. Submission never changes claim state automatically.
Each record mirrors the canonical machine registry. No new Gap or alternate API is created here.
OEG-CML-001 · CML-PDRE-001
Independent third-party validation of the reported 800VDC / SST deployment is established.
NOT_ESTABLISHED
GAP_ID
OEG-CML-001
CASE_ID
CML-PDRE-001
CLAIM
Independent third-party validation of the reported 800VDC / SST deployment is established.
CURRENT STATE
NOT_ESTABLISHED
SCOPE
One operator-reported deployment at one named campus; no independent performance validation is established.
EVIDENCE CUTOFF
2026-09-20T10:46:47Z
WHAT IS ESTABLISHED
One named operator reported commercial operation of a materially relevant 10kV AC to SST to 800VDC architecture.
WHAT IS NOT ESTABLISHED
Independent verification of operating conditions, performance, availability, efficiency, or safety at the named site.
WHAT WOULD CHANGE THIS
An independently attributable operating or test record tied to the named site, with observation period, conditions, method, and responsible organization.
ACCEPTABLE SOURCES
Independent engineering test report
Operator record with attributable methodology
Third-party commissioning or performance record
NON-QUALIFYING SOURCES
Vendor marketing copy
Unattributed screenshots
A second retelling of the operator's original announcement
The 800VDC / SST architecture has been replicated by multiple independent entities.
NOT_ESTABLISHED
GAP_ID
OEG-CML-002
CASE_ID
CML-PDRE-001
CLAIM
The 800VDC / SST architecture has been replicated by multiple independent entities.
CURRENT STATE
NOT_ESTABLISHED
SCOPE
The public record supports a single operator-reported instance, not replication across independent operators or sites.
EVIDENCE CUTOFF
2026-09-20T10:46:47Z
WHAT IS ESTABLISHED
A single named operator reported one materially relevant field deployment.
WHAT IS NOT ESTABLISHED
A second independently attributable deployment
Multi-operator replication
Repeat procurement or industry adoption
WHAT WOULD CHANGE THIS
A public record for another attributable operator or independently controlled site showing a materially comparable deployed architecture and operating status.
ACCEPTABLE SOURCES
Named operator commissioning record
Regulatory or grid-connection record
Independent case study identifying operator, site, architecture, and date
A named customer sodium-ion stationary BESS site has been commissioned.
NOT_ESTABLISHED
GAP_ID
OEG-BESS-001
CASE_ID
SE-BESS-SODIUM-001
CLAIM
A named customer sodium-ion stationary BESS site has been commissioned.
CURRENT STATE
NOT_ESTABLISHED
SCOPE
Stationary sodium-ion BESS only; vehicle, starter-battery, and solid-state battery claims are excluded.
EVIDENCE CUTOFF
2026-09-24
WHAT IS ESTABLISHED
A stationary sodium-ion BESS product launch
A public supply cooperation agreement
Future delivery milestones stated by manufacturers
WHAT IS NOT ESTABLISHED
Completed customer delivery
Named-site commissioning or grid connection
Customer acceptance
WHAT WOULD CHANGE THIS
A public, attributable record identifying the customer or operator, site, sodium-ion stationary system, commissioning or grid-connection date, and operational status.
ACCEPTABLE SOURCES
Customer acceptance record
Named-site commissioning notice
Grid-connection or regulator record tied to the system
Independent field-performance evidence for sodium-ion stationary BESS is established.
NOT_ESTABLISHED
GAP_ID
OEG-BESS-002
CASE_ID
SE-BESS-SODIUM-001
CLAIM
Independent field-performance evidence for sodium-ion stationary BESS is established.
CURRENT STATE
NOT_ESTABLISHED
SCOPE
Public evidence reviewed for stationary sodium-ion BESS; manufacturer-attributed product claims are not independent field-performance evidence.
EVIDENCE CUTOFF
2026-09-24
WHAT IS ESTABLISHED
The product was publicly launched and showcased
Manufacturer-attributed performance and field-validation language exists
WHAT IS NOT ESTABLISHED
Independent field measurements
Attributable operating duration and conditions
Independent safety or performance validation
WHAT WOULD CHANGE THIS
Attributable independent field-operation or performance evidence collected after commissioning at a named stationary sodium-ion BESS. It should identify the responsible operator or third party, site and system, commissioning status, observation period, operating conditions, and method. Evidence may report one or more relevant measures—such as operating duration, availability, delivered capacity or energy, degradation, cycle history, or reliability; all measures are not required at once.
ACCEPTABLE SOURCES
Independent post-commissioning field report with attributable methods
Operator record reporting operating duration, availability, delivered capacity or energy, degradation, cycle history, or reliability
Regulator or research-institute field evaluation tied to a named commissioned system
NON-QUALIFYING SOURCES
Manufacturer brochure or generic product specification
A hospital-specific aggregate outcome dataset has been acquired for this public NSCLC case.
NOT_ESTABLISHED
GAP_ID
OEG-ONC-001
CASE_ID
SE-ONC-NSQNSCLC-CN-001
CLAIM
A hospital-specific aggregate outcome dataset has been acquired for this public NSCLC case.
CURRENT STATE
NOT_ESTABLISHED
SCOPE
China non-squamous NSCLC; the detailed index cohort is EGFR-mutated locally advanced or metastatic disease after EGFR-TKI progression.
EVIDENCE CUTOFF
2026-09-28
WHAT IS ESTABLISHED
Public regulatory, randomized-trial, guideline, surgical-cohort, ECMO-context, and transplant-consensus sources were identified within their stated scopes.
WHAT IS NOT ESTABLISHED
An authorized hospital-specific aggregate dataset for the index cohort
Hospital-level exposure, follow-up, survival, adverse-event, or patient-feedback outcomes for this case
WHAT WOULD CHANGE THIS
A lawful public aggregate dataset or citable public analysis with a defined hospital population, cohort criteria, treatment exposure, outcome definitions, follow-up, censoring, and permitted reuse boundary.
ACCEPTABLE SOURCES
Peer-reviewed hospital aggregate study
Public registry analysis with cohort and censoring definitions
Authorized de-identified aggregate report with reuse terms
NON-QUALIFYING SOURCES
Patient-identifiable data
Anecdotes
Hospital marketing claims
Aggregate numbers without cohort or outcome definitions
Ivonescimab with pemetrexed and carboplatin was approved in China for the defined post-EGFR-TKI non-squamous NSCLC indication.
SUPPORTED
GAP_ID
OEG-ONC-002
CASE_ID
SE-ONC-NSQNSCLC-CN-001
CLAIM
Ivonescimab with pemetrexed and carboplatin was approved in China for the defined post-EGFR-TKI non-squamous NSCLC indication.
CURRENT STATE
SUPPORTED
SCOPE
Population-level regulatory status in China for EGFR-mutated locally advanced or metastatic non-squamous NSCLC progressing after EGFR-TKI; other populations, treatment lines, combinations, and jurisdictions are outside this claim.
EVIDENCE CUTOFF
2026-09-28
WHAT IS ESTABLISHED
An official NMPA public record supports approval of ivonescimab with pemetrexed and carboplatin for the defined China indication.
WHAT IS NOT ESTABLISHED
Approval for populations, treatment lines, combinations, or jurisdictions outside the regulator-defined scope
Comparative superiority or outcome claims beyond the cited evidence
WHAT WOULD CHANGE THIS
An official regulator record that changes, narrows, expands, suspends, withdraws, or corrects the approval status, label, combination, population, or treatment-line scope; or an authoritative correction or retraction of the cited regulatory source.
ACCEPTABLE SOURCES
NMPA approval label or official indication update
Official regulator safety, suspension, withdrawal, or correction notice
Authoritative source correction tied to the cited approval